AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28647339 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1500mg/day for 7 days)
Number of subjects: 55
Study 28647339 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 55
Study 26521100 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (loading/maintenance dose: 20/3.75mg)
Number of subjects: 1363
Study 26521100 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300/75mg)
Number of subjects: 1363
Study 26521100 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1363
Study 26521100 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1363
Study 26521100 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel and Clopidogrel
Number of subjects: 1363
Study 25488088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to deliver vaginally
Number of subjects: 13
Study 25488088 — intervention group
Group type: COMPARATOR
Intervention: Intention to deliver by caesarean section
Number of subjects: 13
Study 23106754 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Rs (Rights, Respect and Responsibility) health self-advocacy training program
Number of subjects: 31
Study 23106754 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 19874179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Number of subjects: 118
Study 19874179 — intervention group
Group type: COMPARATOR
Intervention: Control (Dual/mixed-tropic viruses)
Number of subjects: 118
Study 16646213 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hr of continuous loud reading
Number of subjects: 25
Study 16646213 — intervention group
Group type: COMPARATOR
Intervention: Silent reading with brief periods of conversation (Control)
Number of subjects: 25
Study 12947143 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 101
Study 12947143 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 101
Study 12947143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 101
Study 11367898 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after modified radical mastectomy
Number of subjects: 0
Study 11367898 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic treatment
Number of subjects: 0
Study 9028057 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL) at doses of 0.5, 1.0 and 1.5 mg/kg every 48 hours
Number of subjects: 12
Study 9028057 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL)
Number of subjects: 12
Study 1506125 — intervention group
Group type: EXPERIMENTAL
Intervention: imidazole 2-hydroxybenzoate (750 mg, t.i.d., for three days)
Number of subjects: 10
Study 1506125 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 6360263 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen RSHZ (rifampicin, streptomycin, isoniazid, pyrazinamide) daily for 3 months
Number of subjects: 0
Study 6360263 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen RSHZ/SHZ (rifampicin discontinued after 3 months, remaining drugs given twice weekly for 2 months)
Number of subjects: 0
Study 6360263 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen SHZ/SHZ (similar to RSHZ/SHZ but excluding rifampicin)
Number of subjects: 0
Study 6360263 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic 3-month regimen followed by unsupervised maintenance therapy with isoniazid for a further 3 months
Number of subjects: 0
Study 6360263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent administration of rifampicin
Number of subjects: 0
Study 31094610 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching with long rest duration (90 s)
Number of subjects: 16
Study 31094610 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching with normal rest duration (30 s)
Number of subjects: 16
Study 31094610 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching with short rest duration (10 s)
Number of subjects: 16
Study 31094610 — intervention group
Group type: COMPARATOR
Intervention: Static stretching (all durations)
Number of subjects: 16
Study 30797238 — intervention group
Group type: EXPERIMENTAL
Intervention: PROM‐based patient decision aid and surgeon report
Number of subjects: 0
Study 30797238 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28339404 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT+TENS
Number of subjects: 46
Study 28339404 — intervention group
Group type: COMPARATOR
Intervention: TRT+PLBO
Number of subjects: 46
Study 25226843 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) combined with systemic sorafenib (400 mg twice a day)
Number of subjects: 41
Study 23541513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature Adventure Rehabilitation (NAR)
Number of subjects: 22
Study 23541513 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) control group
Number of subjects: 22
Study 21461059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tip portion of manubrium mallei cut off without desepithelisation (non-desepithelised group)
Number of subjects: 35
Study 21461059 — intervention group
Group type: COMPARATOR
Intervention: Tip portion of manubrium mallei cut off after meticulous desepithelisation (desepithelised group)
Number of subjects: 35
Study 20011182 — intervention group
Group type: EXPERIMENTAL
Intervention: MATTS trial patients (surgical arm of the randomized clinical trial)
Number of subjects: 282
Study 20011182 — intervention group
Group type: COMPARATOR
Intervention: Non-MATTS patients (surgically treated patients not included in the trial)
Number of subjects: 282
Study 20011182 — intervention group
Group type: EXPERIMENTAL
Intervention: MATTS trial patients
Number of subjects: 282
Study 20011182 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MATTS and non-MATTS)
Number of subjects: 282
Study 20011182 — intervention group
Group type: COMPARATOR
Intervention: Non-MATTS patients
Number of subjects: 282
Study 16863657 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 L1 VLP vaccine
Number of subjects: 16
Study 16863657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15547020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg twice daily)
Number of subjects: 5126
Study 15547020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to nicorandil)
Number of subjects: 5126
Study 11518472 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 74
Study 9622285 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (ethyl esters) 2 g/day
Number of subjects: 935
Study 9622285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 935
Study 8155434 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream
Number of subjects: 12
Study 8155434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2970456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 0
Study 2970456 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg
Number of subjects: 0
Study 2970456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg
Number of subjects: 0
Study 2970456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 400 mg
Number of subjects: 0
Study 2970456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29084093 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation Training Mask (ETM)
Number of subjects: 20
Study 29084093 — intervention group
Group type: COMPARATOR
Intervention: No Mask (NM)
Number of subjects: 20
Study 27585605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 55
Study 27585605 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 55
Study 27585605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 25986018 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DHA (0.86%) and AA (0.91%) supplementation
Number of subjects: 129
Study 25986018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 129
Study 25986018 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DHA and AA supplementation
Number of subjects: 129
Study 23601026 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing sequential therapy (LCS)
Number of subjects: 148
Study 23601026 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing quadruple therapy (LCQ)
Number of subjects: 148
Study 20498324 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 200 mg daily
Number of subjects: 15
Study 20498324 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 600 mg daily
Number of subjects: 15
Study 20498324 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 1,000 mg daily
Number of subjects: 15
Study 20498324 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 1,200 mg daily
Number of subjects: 15
Study 20498324 — intervention group
Group type: COMPARATOR
Intervention: Standard antituberculosis treatment
Number of subjects: 15
Study 18391291 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller angles of visual rotation
Number of subjects: 0
Study 18391291 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing trials
Number of subjects: 0
Study 18391291 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice
Number of subjects: 0
Study 16473460 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of the motor cortex using an investigational implantable pulse generator (IPG) set at 30 Hz, 3 mA, and 250 micros pulse width for Patient 1; 50 Hz, 5 mA, and 250 micros pulse width for Patient 2
Number of subjects: 2
Study 14586602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation frequency of 130 Hz
Number of subjects: 5
Study 14586602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation frequency of 180 Hz
Number of subjects: 5
Study 14586602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation frequency of 250 Hz
Number of subjects: 5
Study 14586602 — intervention group
Group type: COMPARATOR
Intervention: Stimulation frequency of 5 Hz
Number of subjects: 5
Study 14586602 — intervention group
Group type: COMPARATOR
Intervention: Stimulation frequency of 50 Hz
Number of subjects: 5
Study 10793126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 56
Study 10793126 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 56
Study 10793126 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy alone or with imipramine
Number of subjects: 56
Study 10176028 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8227460 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (DDI) 375 mg twice daily for 4 days
Number of subjects: 0
Study 8227460 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (DDI) 375 mg twice daily for 4 days with Ketoconazole (KET) 200 mg daily for 4 days
Number of subjects: 0
Study 8227460 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (KET) 200 mg daily for 4 days
Number of subjects: 0
Study 2979066 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic doses of fentanyl (46 +/- 1.3 micrograms/kg) and oxygen (group I)
Number of subjects: 23
Study 2979066 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of fentanyl (3 to 4.7 micrograms/kg; mean = 3.54 +/- 0.1 micrograms/kg) + etomidate (0.4 mg/kg) intravenously (IV) (group II)
Number of subjects: 23
Study 29697768 — intervention group
Group type: EXPERIMENTAL
Intervention: NDV-3A vaccine (1 intramuscular dose)
Number of subjects: 188
Study 29697768 — intervention group
Group type: EXPERIMENTAL
Intervention: NDV-3A vaccine
Number of subjects: 188
Study 26832428 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 90% medical‐grade kanuka honey and 10% glycerine applied twice daily for 12 weeks after washing with antibacterial soap.
Number of subjects: 136
Study 26832428 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial soap (Protex, triclocarban‐based) applied twice daily for 12 weeks.
Number of subjects: 136
Study 26832428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (honey product and control)
Number of subjects: 136
Study 25070094 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesun‐Plus (fixed-dose combination of artesunate and amodiaquine)
Number of subjects: 31
Study 25070094 — intervention group
Group type: COMPARATOR
Intervention: Artesunate Amodiaquine Winthrop (WHO-designated comparator product)
Number of subjects: 31
Study 22856504 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured ongoing group self-management education maintained over two years
Number of subjects: 240
Study 22856504 — intervention group
Group type: COMPARATOR
Intervention: Initial education only (Control)
Number of subjects: 240
Study 19434421 — intervention group
Group type: EXPERIMENTAL
Intervention: Crank length 19% of FR, crank width 72% of SB
Number of subjects: 25
Study 19434421 — intervention group
Group type: EXPERIMENTAL
Intervention: Crank length 22.5% of FR, crank width 85% of SB
Number of subjects: 25
Study 19434421 — intervention group
Group type: EXPERIMENTAL
Intervention: Crank length 26% of FR, crank width 98% of SB
Number of subjects: 25
Study 19434421 — intervention group
Group type: EXPERIMENTAL
Intervention: Crank length short (19% of FR)
Number of subjects: 25
Study 19434421 — intervention group
Group type: EXPERIMENTAL
Intervention: Crank length long (26% of FR)
Number of subjects: 25
Study 18004926 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Snap attachment with 50g force
Number of subjects: 30
Study 18004926 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Snap attachment with 100g force
Number of subjects: 30
Study 18004926 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Snap attachment with 150g force
Number of subjects: 30
Study 18004926 — intervention group
Group type: COMPARATOR
Intervention: Control group with stainless steel ligature wires
Number of subjects: 30
Study 18004926 — intervention group
Group type: COMPARATOR
Intervention: Control group with 150g force
Number of subjects: 30
Study 18004926 — intervention group
Group type: COMPARATOR
Intervention: Control group with 50g force
Number of subjects: 30
Study 15228198 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic group
Number of subjects: 118
Study 15228198 — intervention group
Group type: COMPARATOR
Intervention: Non-athletic group
Number of subjects: 118
Study 12475453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin (0.5 mg/kg)
Number of subjects: 242
Study 12475453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin (0.5 mg/kg) with eptifibatide
Number of subjects: 242
Study 9839521 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) + leucovorin (LV)
Number of subjects: 2176
Study 9839521 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) + leucovorin (LV) + interferon alfa-2a (IFN)
Number of subjects: 2176
Study 7795721 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil (1 ml, 2% solution)
Number of subjects: 116
Study 7795721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine (2.5 g, 10% ointment)
Number of subjects: 116
Study 7795721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 2173049 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium
Number of subjects: 37
Study 2173049 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 798582 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (300 mg per day)
Number of subjects: 0
Study 798582 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0
Study 798582 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 30966942 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction equations for estimating VO2peak using waist circumference and body fat
Number of subjects: 326
Study 30966942 — intervention group
Group type: COMPARATOR
Intervention: Previously published equations for estimating VO2peak
Number of subjects: 326
Study 30966942 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of VO2peak from the 20-m PACER test
Number of subjects: 326
Study 29112701 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel treatment for <6 cycles
Number of subjects: 804
Study 29112701 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel treatment for 6 cycles
Number of subjects: 804
Study 29112701 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel treatment for >6 cycles
Number of subjects: 804
Study 29112701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and docetaxel
Number of subjects: 804
Study 29112701 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus placebo
Number of subjects: 804
Study 26090821 — intervention group
Group type: EXPERIMENTAL
Intervention: Project EX intervention
Number of subjects: 1546
Study 23467946 — intervention group
Group type: EXPERIMENTAL
Intervention: HTS 5% bolus (125 cc every 6 hrs, N: 11)
Number of subjects: 33
Study 23467946 — intervention group
Group type: EXPERIMENTAL
Intervention: HTS 5% infusion (500 cc for 24 hrs, N: 12)
Number of subjects: 33
Study 23467946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 20% (1 g/kg bolus, repeated 0.25‐0.5 g/kg every 6 hrs for 3 days, N: 10)
Number of subjects: 33
Study 21306792 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive dissection of recurrent laryngeal nerve (RLN)
Number of subjects: 331
Study 21306792 — intervention group
Group type: COMPARATOR
Intervention: Non-extensive dissection of recurrent laryngeal nerve (RLN)
Number of subjects: 331
Study 21306792 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive dissection of RLN
Number of subjects: 331
Study 20050165 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking mineral waters (alkaline, sodium hydrocarbonate or boron‐containing water with elevated fluorine and chlorine content)
Number of subjects: 0
Study 21843204 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention group (n = 83)
Number of subjects: 168
Study 21843204 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 85)
Number of subjects: 168
Study 16404978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidumbacterin forte
Number of subjects: 1000
Study 16404978 — intervention group
Group type: EXPERIMENTAL
Intervention: Probifor
Number of subjects: 1000
Study 16404978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidin
Number of subjects: 1000
Study 16404978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifilis
Number of subjects: 1000
Study 16404978 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcidum
Number of subjects: 1000
Study 16404978 — intervention group
Group type: EXPERIMENTAL
Intervention: Florin forte
Number of subjects: 1000
Study 16404978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipol
Number of subjects: 1000
Study 16404978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acilact
Number of subjects: 1000
Study 16404978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 12899584 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 6886
Study 12899584 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 6886
Study 10204903 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic patient education materials (two pamphlets and a video)
Number of subjects: 200
Study 10204903 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no additional educational materials)
Number of subjects: 200
Study 8869363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokinetic subjects (2.7 km/day or 3,000 walking steps/day)
Number of subjects: 20
Study 8869363 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (13.9 km/day or 10,000 running steps/day)
Number of subjects: 20
Study 2407911 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment for alcohol abuse
Number of subjects: 0
Study 2407911 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment for alcohol abuse
Number of subjects: 0
Study 7420722 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented videotape with specific instructions
Number of subjects: 0
Study 7420722 — intervention group
Group type: COMPARATOR
Intervention: Videotape without specific instructions
Number of subjects: 0
Study 31587565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin assay implementation
Number of subjects: 48282
Study 29937301 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMI (peri-procedural myocardial infarction) defined by biomarker elevations ≥3× the upper limit of normal (ULN)
Number of subjects: 13968
Study 29937301 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMI defined by CK-MB elevation 3 to <5× ULN
Number of subjects: 13968
Study 29937301 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMI defined by CK-MB elevation 5 to <10× ULN
Number of subjects: 13968
Study 29937301 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMI defined by CK-MB elevation ≥10× ULN
Number of subjects: 13968
Study 29937301 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMI defined by UDMICK-MB
Number of subjects: 13968
Study 26780348 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9-THC 5mg
Number of subjects: 30
Study 26780348 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9-THC 15mg
Number of subjects: 30
Study 26780348 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9-THC 25mg or 30mg
Number of subjects: 30
Study 26780348 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9-THC (all doses)
Number of subjects: 30
Study 26780348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25573204 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum YKL-40
Number of subjects: 230
Study 25573204 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CTX-MMP/PINP ratio
Number of subjects: 230
Study 25573204 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization status
Number of subjects: 230